Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
REVIEW
Biomarker-guided asthma management: Science fiction or images of the imminent future?
1
2nd Respiratory Medicine Department,
University of Athens Medical School, Athens,
Greece
2
Respiratory Medicine Physician, Trikala,
Greece
Pneumon 2015;28(3):237-243
KEYWORDS
ABSTRACT
Objective:
Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. Although in most asthmatic patients there is a correlation between the level of airway inflammation and the severity of symptoms, in patients with difficult to treat asthma there is often discordance between symptoms and inflammation. Clinicians need easy noninvasive and affordable biomarkers for the recognition of asthmatic inflammation in order to provide optimal and effective therapeutic interventions to their patients.
Data Sources:
We have performed a search on PubMed using the keywords asthma therapy, biomarkers, exhaled NO, induced sputum and inflammation.
Study Selections:
We focused on papers providing results that could be useful in clinical practice. Results: In this review we focus on the treatment of asthmatic patients using biomarkers in biological samples collected using semi-invasive (serum and induced sputum) and non-invasive (exhaled breath condensate, and exhaled air) procedures.
Conclusions:
Asthma research is shifting from studying symptoms expression, lung function and response to medication, to cellular profile, protein analysis and genetic markers, possibly combined with clinical measures. Single biomarker approaches to phenotype asthma do not seem to be accurate and therefore studies combining multiple known biomarkers are needed.
Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. Although in most asthmatic patients there is a correlation between the level of airway inflammation and the severity of symptoms, in patients with difficult to treat asthma there is often discordance between symptoms and inflammation. Clinicians need easy noninvasive and affordable biomarkers for the recognition of asthmatic inflammation in order to provide optimal and effective therapeutic interventions to their patients.
Data Sources:
We have performed a search on PubMed using the keywords asthma therapy, biomarkers, exhaled NO, induced sputum and inflammation.
Study Selections:
We focused on papers providing results that could be useful in clinical practice. Results: In this review we focus on the treatment of asthmatic patients using biomarkers in biological samples collected using semi-invasive (serum and induced sputum) and non-invasive (exhaled breath condensate, and exhaled air) procedures.
Conclusions:
Asthma research is shifting from studying symptoms expression, lung function and response to medication, to cellular profile, protein analysis and genetic markers, possibly combined with clinical measures. Single biomarker approaches to phenotype asthma do not seem to be accurate and therefore studies combining multiple known biomarkers are needed.
REFERENCES (45)
1.
Global Initiative for Asthma 2012: Updated from Global Strategy for Asthma Management and Prevention. Workshop Report 2012. Available at http://www.ginasthma.com/
2.
Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218- 24.
3.
Snell N, Newbold P. The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol 2008;8:222-35.
4.
Kostikas K, Papaioannou AI, Tanou K, Koutsokera A, Papala M, Gourgoulianis KI. Portable exhaled nitric oxide as a screening tool for asthma in young adults during pollen season. Chest 2008;133:906-13.
5.
Hunter CJ, Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002;121:1051-7.
6.
Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004;169:473-8.
7.
Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309-29.
8.
Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163:16931722.
9.
Guo FH, Comhair SA, Zheng S, et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol 2000;164:5970-80.
10.
Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133-5.
11.
Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15.
12.
Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368-70.
13.
Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 2003;123:751-6.
14.
Covar RA, Szefler SJ, Martin RJ, et al. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr 2003;142:469-75.
15.
Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006;11:54-61.
16.
Belda J, Leigh R, Parameswaran K, O’Byrne PM, Sears MR, Hargreave FE. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000;161(2 Pt 1):475-8.
17.
Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005;35:1175-9.
18.
Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax 2010;65:1039-44.
19.
Hargreave FE, Nair P. Point: Is measuring sputum eosinophils useful in the management of severe asthma? Yes. Chest 2011;139:1270-3.
20.
Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and noneosinophilic asthma. Thorax 2007;62:1043-9.
21.
Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9.
22.
Gibson PG. A light at the end of the tunnel of inflammation in obstructive airway diseases? Chest 2008;134:475-6.
23.
Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005;172:453-9.
24.
de Jongste JC, Carraro S, Hop WC, Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009;179:93-7.
25.
Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
26.
Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007;176:231-7.
27.
Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
28.
Chlumsky J, Striz I, Terl M, Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006;34:129-39.
29.
Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199-208.
30.
Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483-94.
31.
Michils A, Baldassarre S, Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J 2008;31:539-46.
32.
Michils A, Louis R, Peche R, Baldassarre S, Van Muylem A. Exhaled nitric oxide as a marker of asthma control in smoking patients. Eur Respir J 2009;33:1295-301.
33.
Papaioannou AI, Minas M, Tanou K, Gourgoulianis KI, Kostikas K. Exhaled NO may predict loss of asthma control: the effect of concomitant allergic rhinitis. Eur Respir J 2009;34:1006-7.
34.
Harkins MS, Fiato KL, Iwamoto GK. Exhaled nitric oxide predicts asthma exacerbation. J Asthma 2004;41:471-6.
35.
Giannini D, Di Franco A, Cianchetti S, et al. Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients. Clin Exp Allergy 2000;30:1777-84.
36.
Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-93.
37.
Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med 2009;103:1098-113.
38.
Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573-82.
39.
Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187:804-11.
40.
Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.
41.
Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
42.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207.
43.
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoidsparing effect of mepolizumab in eosinophilic asthma. The N Engl J Med 2014;371:1189-97.
44.
Kraft M. Asthma phenotypes and interleukin-13--moving closer to personalized medicine. N Engl J Med 2011;365:1141-4.
45.
Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98.
Share
RELATED ARTICLE
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
